Signum Biosciences

About:

Signum Biosciences develops small molecule therapeutics derived from its STM platform to modulate signal transduction imbalances.

Website: http://www.signumbiosciences.com

Top Investors: NJEDA

Description:

Signum Biosciences is a private biotechnology company dedicated to developing small-molecule therapeutics derived from its Signal Transduction Modulation (STM) platform to modulate signal transduction imbalances. Through research on protein networks that control biological systems, Signum is developing therapeutic agents for several skin conditions, Alzheimer's, Parkinson's, asthma and COPD. Signum's STM technology provides many opportunities for the development of novel consumer products and pharmaceutical candidates.

Total Funding Amount:

$5.6M

Estimated Revenue Range:

$1M to $10M

Headquarters Location:

Boulder, Colorado, United States

Founded Date:

2004-01-01

Contact Email:

info(AT)signumbio.com

Founders:

Gregory Stock, Jeffry Stock, Maxwell Stock

Number of Employees:

11-50

Last Funding Date:

2013-11-15

IPO Status:

Private

Industries:

© 2025 bioDAO.ai